# Phase 165 Handoff

Completed through Phase 165.

Current state:

- Reviewed runtime clean: true.
- Phenotype expansion allowed: false.
- Reviewed source gaps: 0.
- Draft source gaps: 0.
- Active draft phenotype count: 1.
- Active draft: `acute_otitis_media_uncomplicated`.
- Graph: 2067 nodes / 3055 edges.

Phase 161-165 result:

- Accepted clinician decision B: revise and keep draft.
- Adult-only scope added.
- Clinician-entered treatment plan required.
- Antibiotic language revised to defer to clinician instructions.
- Follow-up timing no longer hard-coded.
- Pediatric, recurrent/chronic, perforation/tube, otitis externa, trauma/foreign body, hearing loss, vertigo/facial weakness, immunocompromise, unstable vitals, and specialist-directed ENT plans remain blocked.
- Runtime stress now includes watchful waiting, delayed antibiotic, missing treatment plan, pediatric pathway, ENT-directed plan, tympanostomy tube, and unstable vitals.

Decision:

Keep `acute_otitis_media_uncomplicated` draft only. Do not promote yet.

Next batch recommendation:

Run Phase 166-170 as a retire-vs-promote resolution batch. My recommendation is retire to product-layer fallback unless explicit final clinician approval is given for adult-only AOM ontology mode.

Planned Phase 166-170:

- Phase 166: final AOM promotion safety audit.
- Phase 167: decide promote vs retire.
- Phase 168: if no explicit approval, retire to product-layer fallback.
- Phase 169: rebuild gate and broad ear complaint stress.
- Phase 170: handoff with next candidate ranking plan.
